Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kathleen Corey, M.D.

Co-Author

This page shows the publications co-authored by Kathleen Corey and Raymond Chung.
Connection Strength

9.991
  1. Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. Dig Dis Sci. 2015 Aug; 60(8):2523-8.
    View in: PubMed
    Score: 0.613
  2. The absence of obstructive sleep apnea may protect against non-alcoholic fatty liver in patients undergoing bariatric surgery. PLoS One. 2013; 8(5):e62504.
    View in: PubMed
    Score: 0.537
  3. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2012 Jun; 10(6):651-6.
    View in: PubMed
    Score: 0.493
  4. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol. 2009 Oct; 30(10):1000-5.
    View in: PubMed
    Score: 0.419
  5. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. 2009 Oct; 50(4):1030-7.
    View in: PubMed
    Score: 0.419
  6. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010 Mar; 17(3):201-7.
    View in: PubMed
    Score: 0.414
  7. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009 May; 29(5):748-53.
    View in: PubMed
    Score: 0.400
  8. Treating difficult-to-treat hepatitis C virus infection: we may still need to push the ribavirin envelope. Gastroenterology. 2007 Dec; 133(6):2062-3.
    View in: PubMed
    Score: 0.369
  9. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006 Oct; 4(10):1278-82.
    View in: PubMed
    Score: 0.337
  10. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep. 2021 09 10; 11(1):18045.
    View in: PubMed
    Score: 0.239
  11. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2022 02; 6(2):309-319.
    View in: PubMed
    Score: 0.239
  12. Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With Obesity. Hepatol Commun. 2022 01; 6(1):77-89.
    View in: PubMed
    Score: 0.238
  13. Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase. Cell Mol Gastroenterol Hepatol. 2021; 12(4):1297-1310.
    View in: PubMed
    Score: 0.235
  14. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clin Gastroenterol Hepatol. 2022 02; 20(2):256-268.
    View in: PubMed
    Score: 0.225
  15. Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus. Hepatol Commun. 2020 Aug; 4(8):1206-1217.
    View in: PubMed
    Score: 0.219
  16. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020 06; 20(6):1619-1628.
    View in: PubMed
    Score: 0.214
  17. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2776-2784.e4.
    View in: PubMed
    Score: 0.204
  18. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. Aliment Pharmacol Ther. 2019 05; 49(9):1205-1213.
    View in: PubMed
    Score: 0.201
  19. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018 05 15; 259:198-204.
    View in: PubMed
    Score: 0.190
  20. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity (Silver Spring). 2017 08; 25(8):1313-1316.
    View in: PubMed
    Score: 0.180
  21. MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). Hepatol Commun. 2017 Jul; 1(5):429-438.
    View in: PubMed
    Score: 0.178
  22. Intermittent hypoxia is a proinflammatory stimulus resulting in IL-6 expression and M1 macrophage polarization. Hepatol Commun. 2017 06; 1(4):326-337.
    View in: PubMed
    Score: 0.178
  23. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant. 2016 Apr; 30(4):452-60.
    View in: PubMed
    Score: 0.163
  24. Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016 05; 111(5):671-6.
    View in: PubMed
    Score: 0.163
  25. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci. 2016 07; 61(7):2108-17.
    View in: PubMed
    Score: 0.162
  26. Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2015 Oct 08; 6:e114.
    View in: PubMed
    Score: 0.159
  27. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015; 47(12):924-9.
    View in: PubMed
    Score: 0.157
  28. Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS One. 2014; 9(12):e114747.
    View in: PubMed
    Score: 0.150
  29. Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Radiology. 2015 Mar; 274(3):888-96.
    View in: PubMed
    Score: 0.149
  30. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis. 2014 Jun 21; 13:100.
    View in: PubMed
    Score: 0.145
  31. Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig Dis Sci. 2014 Jan; 59(1):174-82.
    View in: PubMed
    Score: 0.137
  32. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012; 7(2):e27144.
    View in: PubMed
    Score: 0.123
  33. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011 Nov; 56(11):3316-22.
    View in: PubMed
    Score: 0.119
  34. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int. 2011 Mar; 31(3):330-9.
    View in: PubMed
    Score: 0.111
  35. Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology. 2022 Apr; 162(4):1210-1225.
    View in: PubMed
    Score: 0.061
  36. Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. Sci Transl Med. 2021 Oct 20; 13(616):eabe8939.
    View in: PubMed
    Score: 0.060
  37. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021 08 16; 73(4):621-630.
    View in: PubMed
    Score: 0.060
  38. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021 06 15; 72(12):2087-2094.
    View in: PubMed
    Score: 0.059
  39. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep. 2021 05 18; 11(1):10485.
    View in: PubMed
    Score: 0.059
  40. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology. 2021 02; 73(2):548-559.
    View in: PubMed
    Score: 0.057
  41. Association Between Liver Fat and Bone Density is Confounded by General and Visceral Adiposity in a Community-Based Cohort. Obesity (Silver Spring). 2021 03; 29(3):595-600.
    View in: PubMed
    Score: 0.057
  42. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2021 01 23; 106(2):e520-e533.
    View in: PubMed
    Score: 0.057
  43. Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Hepatol Commun. 2021 01; 5(1):133-143.
    View in: PubMed
    Score: 0.057
  44. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology. 2020 11; 72(5):1819-1837.
    View in: PubMed
    Score: 0.056
  45. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020 08 20; 5(16).
    View in: PubMed
    Score: 0.056
  46. Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol. 2020 04; 46(4):972-980.
    View in: PubMed
    Score: 0.054
  47. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. J Hepatol. 2020 06; 72(6):1062-1069.
    View in: PubMed
    Score: 0.053
  48. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab. 2020 02 04; 31(2):406-421.e7.
    View in: PubMed
    Score: 0.053
  49. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 12; 6(12):e821-e830.
    View in: PubMed
    Score: 0.052
  50. Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study. Liver Transpl. 2019 06; 25(6):859-869.
    View in: PubMed
    Score: 0.051
  51. Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2592-2599.
    View in: PubMed
    Score: 0.050
  52. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018 12 01; 4(12):1683-1690.
    View in: PubMed
    Score: 0.049
  53. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis. 2018 09 22; 218(9):1394-1403.
    View in: PubMed
    Score: 0.049
  54. Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity. Hepatol Commun. 2018 Jul; 2(7):786-797.
    View in: PubMed
    Score: 0.048
  55. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 01; 270:245-252.
    View in: PubMed
    Score: 0.048
  56. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology. 2018 05; 67(5):1797-1806.
    View in: PubMed
    Score: 0.047
  57. Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES. Clin Infect Dis. 2017 Aug 15; 65(4):557-565.
    View in: PubMed
    Score: 0.045
  58. Validation of Shear Wave Elastography Cutoff Values on the Supersonic Aixplorer for Practical Clinical Use in Liver Fibrosis Staging. Ultrasound Med Biol. 2017 06; 43(6):1125-1133.
    View in: PubMed
    Score: 0.044
  59. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology. 2017 04; 65(4):1156-1164.
    View in: PubMed
    Score: 0.044
  60. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab. 2016 12 13; 24(6):848-862.
    View in: PubMed
    Score: 0.043
  61. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci. 2016 12; 61(12):3425-3435.
    View in: PubMed
    Score: 0.043
  62. A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. Sci Rep. 2015 Dec 15; 5:18277.
    View in: PubMed
    Score: 0.040
  63. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus. J Am Chem Soc. 2012 Apr 25; 134(16):6896-9.
    View in: PubMed
    Score: 0.031
  64. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. Dig Dis Sci. 2010 Sep; 55(9):2629-35.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.